- Home
- HKD vs TSHA Comparison
HKD vs TSHA Comparison
Compare HKD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- TSHA
- Stock Information
- Founded
- HKD 2003
- TSHA 2019
- Country
- HKD France
- TSHA United States
- Employees
- HKD N/A
- TSHA N/A
- Industry
- HKD Finance: Consumer Services
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- TSHA Health Care
- Exchange
- HKD Nasdaq
- TSHA Nasdaq
- Market Cap
- HKD 656.8M
- TSHA 728.4M
- IPO Year
- HKD 2022
- TSHA 2020
- Fundamental
- Price
- HKD $1.82
- TSHA $2.89
- Analyst Decision
- HKD
- TSHA Strong Buy
- Analyst Count
- HKD 0
- TSHA 7
- Target Price
- HKD N/A
- TSHA $8.71
- AVG Volume (30 Days)
- HKD 358.4K
- TSHA 3.5M
- Earning Date
- HKD 01-01-0001
- TSHA 11-12-2025
- Dividend Yield
- HKD N/A
- TSHA N/A
- EPS Growth
- HKD 9.93
- TSHA N/A
- EPS
- HKD 0.23
- TSHA N/A
- Revenue
- HKD $20,445,000.00
- TSHA $8,098,000.00
- Revenue This Year
- HKD N/A
- TSHA N/A
- Revenue Next Year
- HKD N/A
- TSHA N/A
- P/E Ratio
- HKD $7.68
- TSHA N/A
- Revenue Growth
- HKD N/A
- TSHA N/A
- 52 Week Low
- HKD $1.55
- TSHA $1.05
- 52 Week High
- HKD $5.80
- TSHA $3.40
- Technical
- Relative Strength Index (RSI)
- HKD 54.83
- TSHA 44.47
- Support Level
- HKD $1.57
- TSHA $3.16
- Resistance Level
- HKD $1.86
- TSHA $2.99
- Average True Range (ATR)
- HKD 0.07
- TSHA 0.19
- MACD
- HKD -0.07
- TSHA -0.04
- Stochastic Oscillator
- HKD 94.79
- TSHA 11.38
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment, hotel operations, hospitality and VIP services segment and media and entertainment services. The company generates maximum revenue by providing financial digital solutions through its insurance brokerage services and other digital solutions services. Geographically, the company generates maximum revenue from Hong Kong and Singapore.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.